Search Within

Sloan Kettering Institute Postdocs

Formats
  1. Journal Article (8036)
  2. Meeting Abstract (3693)
  3. Review (630)
  4. Editorial (262)
  5. Book Section (195)
  6. Conference Paper (161)
  7. Research Letter (139)
  8. Correspondence (68)
  9. Miscellaneous (67)
  10. Guidelines (30)
  11. Book Whole (6)
Groups
  1. GSK Faculty (6363)
  2. Department of Medicine (4809)
  3. Sloan Kettering Institute Faculty (3570)
  4. Center for Molecular Imaging and Biotechnology (CMIB) (3037)
  5. Surgery (2633)
  6. Solid Tumor Oncology Division (2604)

More Groups

People
  1. Britta Weigelt (376)
  2. Jorge Reis-Filho (328)
  3. Mithat Gonen (318)
  4. Marc Ladanyi (309)
  5. Michael Berger (288)
  6. Joseph Deasy (285)

More People

Years
  1. 2026 (1)
  2. 2025 (697)
  3. 2024 (1080)
  4. 2023 (1152)
  5. 2022 (1366)
  6. 2021 (1179)

More Years

Publications
  1. Blood (680)
  2. Cancer Research (543)
  3. Journal of Clinical Oncology (431)
  4. Journal of Nuclear Medicine (271)
  5. Annals of Surgical Oncology (264)
  6. Clinical Cancer Research (249)

More Publications

Publishers
  1. Nature Publishing Group (1349)
  2. Elsevier Inc. (1106)
  3. American Association for Cancer Research (1058)
  4. Springer (840)
  5. American Society of Hematology (740)
  6. Cell Press (740)

More Publishers

Results (13287)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Clinical, pathological and molecular disease characteristics of diffuse hemispheric glioma, H3 G34-mutant
    Meeting Abstract

    Le Rhun, E.; Bink, A.; Felsberg, J.; Gramatzki, D.; Brandner, S.; Benhamida, J. K.; Wick, A.; Tonn, J. C.; Mohme, M.; Tabatabai, G.; more...
    Neuro-Oncology (2024)

    Fulltext@MSK | Save
  • Utility of circulating tumor DNA (CTDNA) from cerebrospinal fluid (CSF) for prognosis of patients with recurrent high-grade glioma
    Meeting Abstract

    Holle, B. M.; Nandakumar, S.; Kreitzer, C.; Song, T.; Tartaro, M.; Hertz, C. A. J.; Rafailov, J.; Campos, C.; Reiner, A. S.; Young, R.; more...
    Neuro-Oncology (2024)

    Fulltext@MSK | Save
  • CXCL1 mediates leptomeningeal metastasis growth
    Meeting Abstract

    Osman, A.; Remsik, J.; Wijetunga, A.; Snyder, J.; Manoranjan, B.; Nobre, A.; Freret, M.; Guber, D.; Chabot, K.; Piedrafita-Ortiz, S.; more...
    Neuro-Oncology (2024)

    Fulltext@MSK | Save
  • Safety, tolerability, and clinical assessment of bemdaneprocel for Parkinson's disease: Results up to 18 months from a phase 1 study
    Meeting Abstract

    Henchcliffe, C.; Sarva, H.; Lozano, A.; Fasano, A.; Kalia, S.; Yu, K. K. H.; Brennan, C.; Stemple, W.; Abid, N.; Yountz, M.; more...
    Molecular Therapy (2024)

    Fulltext@MSK | Save
  • Identifying and exploiting cell-state dependent metabolic networks
    Meeting Abstract

    Finley, L.
    Journal of Biological Chemistry (2024)

    Fulltext@MSK | Save
  • Systemic anti-ceramide immunotherapy corrects diabetic retinopathy by restoring hematopoietic stem cell function
    Meeting Abstract

    Dorweiler, T. F.; Singh, A.; O'Reilly, S.; Blanchard, G.; Grant, M. B.; Kolesnick, R.; Busik, J. V.
    Investigative Ophthalmology & Visual Science (IOVS) (2024)

    Fulltext@MSK | Save
  • Characteristics of patients and management of ocular adverse events after treatment with belantamab mafodotin (belamaf) in relapsed/refractory multiple myeloma (RRMM): A real-world study in Europe
    Meeting Abstract

    Cavo, M.; Delforge, M.; Dimopoulos, M.; Escalante-Barrigon, F.; Hultcrantz, M.; Kleinman, D.; Lee, H.; Vij, R.; Greil, R.; Melchardt, T.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Defining the rates of cytokine release syndrome associated with Talquetamab step-up doses
    Meeting Abstract

    Hamadeh, I.; Shekarkhand, T.; Rueda, C.; Firestone, R.; Wang, A.; Korde, N.; Hultcrantz, M.; Lesokhin, A.; Mailankody, S.; Hassoun, H.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Increased WEE1 expression is predictive of short progression-free survival, independent of standard prognostic factors in multiple myeloma
    Meeting Abstract

    Simhal, A.; Firestone, R.; Oh, J. H.; Norton, L.; Usmani, S.; Deasy, J.; Maclachlan, K.
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Comprehensive genomic sequencing predicts sub-optimal response to bispecific antibodies (BsAb) and chimeric antigen receptor T cells (CAR-T) in multiple myeloma (MM)
    Meeting Abstract

    Maclachlan, K.; Shekarkhand, T.; Farzana, T.; Costa, B.; Firestone, R.; Jurgens, E.; Rajeeve, S.; Hashmi, H.; Hassoun, H.; Shah, U.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save